Latest Vitasora Health (ASX:VHL) News

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Vitasora Health Limited reported a significant 22% increase in daily clinical billing productivity for the December 2025 quarter, alongside a 17% rise in operating revenue. With new CMS reimbursement policies now in effect, the company anticipates a further 10–20% revenue uplift in 2026.

Vitasora Health has completed an A$11 million capital raise, including a cornerstone investment, bolstering its balance sheet to support ambitious growth in the US healthcare market. The company targets cash flow breakeven by the end of FY2026 amid expanding patient programs and new partnerships.

Vitasora Health has secured AU$3.56 million from a cornerstone investor, issuing over 118 million shares, while confirming compliance with key regulatory disclosure obligations.

Vitasora Health Limited reported robust patient program growth and secured new US partnerships, driving revenue above A$1 million for the quarter. A recent A$11 million capital raise positions the company for continued expansion and cash-flow breakeven by late 2026.

Vitasora Health is set to scale its AI-powered chronic care services from Hawaii to 10-15 US states, leveraging a new partnership with Privia Health following Evolent Care Partners' divestiture. This expansion targets up to 30,000 patients and promises significant revenue growth in 2026.

Vitasora Health has received $2.43 million from a cornerstone investor, advancing its $11 million capital raise and reinforcing its path to profitability by Q4 FY2026. The company’s expanding US partnerships and technology investments signal growing market confidence.

Vitasora Health reported a sharp rise in losses and operating cash outflows for FY2025, despite achieving significant cost savings from its Orb Health acquisition. The company faces a material uncertainty over its ability to continue as a going concern.

Vitasora Health has expanded its partnership with Tampa Family Health Centers to deliver chronic care and remote monitoring services to 7,000 Medicaid patients, unlocking over US$4 million in annual revenue. This marks a pioneering step for Florida’s largest Federally Qualified Health Center in adopting value-based care for underserved communities.

Vitasora Health Limited reported a remarkable 226% increase in patient programs and secured an $11 million capital raise, positioning the company for accelerated growth and a path to cash flow breakeven in late 2026.

Vitasora Health has completed the first tranche of its $11 million capital raise, positioning the company to fund growth initiatives and reach cash flow breakeven in the second half of fiscal 2026.

Vitasora Health has secured approximately A$11 million in capital to accelerate its expansion in the US remote patient monitoring market, highlighted by an upgraded contract with TPAC covering 15,000 patients. The company targets a USD 18 million annual recurring revenue run-rate by late 2026.